In a rare move, nonprofit organization Blood Cancer United is buying the remaining supplies of a discontinued investigational ...

Daraxonrasib doubles survival — a RAS‑targeting drug development breakthrough.

Cancer drug development has never moved faster. Yet, for too many patients, the next treatment decision still begins with ...

GLP-1 drugs aren’t just reducing weight — they may also be reducing the chances of developing one of the most common and ...

For decades, pancreatic cancer has been one of the most lethal cancers, with few effective treatment options. A new drug, daraxonrasib, targets the KRAS mutation that fuels most pancreatic ...

A distinct signaling pathway called TNF- drives the transformation of epithelial cells into aggressive tumor cells. During cancer progression, cells activate their own TNF- program and become invasive ...

A retrospective analysis of more than 110,000 women between the ages of 45 and 80 found that those who took GLP-1 medications ...

The same cellular renewal that keeps our bodies healthy might also fuel the growth of cancer. A UC Merced biologist has found that the brain could hold the key to stopping it. Professor Néstor Oviedo, ...

Cancer screening can feel like a rite of passage as we get older: skin cancer checks in your late 30s, a mammogram at age 40, a colonoscopy at age 45. However, as young cancer cases have skyrocketed, ...